154 related articles for article (PubMed ID: 23991922)
1. Romidepsin for peripheral T-cell lymphoma.
Khot A; Dickinson M; Prince HM
Expert Rev Hematol; 2013 Aug; 6(4):351-9. PubMed ID: 23991922
[TBL] [Abstract][Full Text] [Related]
2. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
Iyer SP; Foss FF
Oncologist; 2015 Sep; 20(9):1084-91. PubMed ID: 26099743
[TBL] [Abstract][Full Text] [Related]
3. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
Shimony S; Horowitz N; Ribakovsky E; Rozovski U; Avigdor A; Zloto K; Berger T; Avivi I; Perry C; Abadi U; Raanani P; Gafter-Gvili A; Gurion R
Hematol Oncol; 2019 Dec; 37(5):569-577. PubMed ID: 31674027
[TBL] [Abstract][Full Text] [Related]
4. Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
Foss F; Pro B; Miles Prince H; Sokol L; Caballero D; Horwitz S; Coiffier B
Cancer Med; 2017 Jan; 6(1):36-44. PubMed ID: 27981793
[TBL] [Abstract][Full Text] [Related]
5. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.
Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Borchmann P; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan S; Shustov A; Nichols J; Carroll S; Balser J; Balser B; Horwitz S
J Clin Oncol; 2012 Feb; 30(6):631-6. PubMed ID: 22271479
[TBL] [Abstract][Full Text] [Related]
6. [Romidepsin (Istodax
Ro T; Nakayama N; Achiwa H; Ohtsu T
Nihon Yakurigaku Zasshi; 2018; 151(3):122-129. PubMed ID: 29526921
[TBL] [Abstract][Full Text] [Related]
7. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.
Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan Iyer S; Shustov A; Nielsen T; Nichols J; Wolfson J; Balser B; Horwitz S
J Hematol Oncol; 2014 Jan; 7():11. PubMed ID: 24456586
[TBL] [Abstract][Full Text] [Related]
8. Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials.
Shustov A; Coiffier B; Horwitz S; Sokol L; Pro B; Wolfson J; Balser B; Eisch R; Popplewell L; Prince HM; Allen SL; Piekarz R; Bates S
Leuk Lymphoma; 2017 Oct; 58(10):2335-2341. PubMed ID: 28264616
[TBL] [Abstract][Full Text] [Related]
9. Romidepsin is effective and well-tolerated in patients ≥60 years old with relapsed or refractory peripheral T-cell lymphoma (PTCL): analysis from phase 2 trials.
Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 5):17-8. PubMed ID: 24852793
[No Abstract] [Full Text] [Related]
10. Romidepsin: in the treatment of T-cell lymphoma.
Yang LP
Drugs; 2011 Jul; 71(11):1469-80. PubMed ID: 21812508
[TBL] [Abstract][Full Text] [Related]
11. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.
Foss F; Horwitz S; Pro B; Prince HM; Sokol L; Balser B; Wolfson J; Coiffier B
J Hematol Oncol; 2016 Mar; 9():22. PubMed ID: 26965915
[TBL] [Abstract][Full Text] [Related]
12. Novel agents in development for peripheral T-cell lymphoma.
O'Connor OA
Semin Hematol; 2010 Apr; 47 Suppl 1():S11-4. PubMed ID: 20359580
[TBL] [Abstract][Full Text] [Related]
13. Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma.
Marchi E; Raufi AG; O'Connor OA
Hematol Oncol Clin North Am; 2017 Apr; 31(2):359-375. PubMed ID: 28340883
[TBL] [Abstract][Full Text] [Related]
14. New perspectives in the therapeutic approach of peripheral T-cell lymphoma.
Gisselbrecht C; Sibon D
Curr Opin Oncol; 2018 Sep; 30(5):285-291. PubMed ID: 30096094
[TBL] [Abstract][Full Text] [Related]
15. Romidepsin: a novel histone deacetylase inhibitor for cancer.
Bertino EM; Otterson GA
Expert Opin Investig Drugs; 2011 Aug; 20(8):1151-8. PubMed ID: 21699444
[TBL] [Abstract][Full Text] [Related]
16. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.
Falchi L; Ma H; Klein S; Lue JK; Montanari F; Marchi E; Deng C; Kim HA; Rada A; Jacob AT; Kinahan C; Francescone MM; Soderquist CR; Park DC; Bhagat G; Nandakumar R; Menezes D; Scotto L; Sokol L; Shustov AR; O'Connor OA
Blood; 2021 Apr; 137(16):2161-2170. PubMed ID: 33171487
[TBL] [Abstract][Full Text] [Related]
17. The discovery and development of romidepsin for the treatment of T-cell lymphoma.
Smolewski P; Robak T
Expert Opin Drug Discov; 2017 Aug; 12(8):859-873. PubMed ID: 28641053
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.
Piekarz RL; Frye R; Prince HM; Kirschbaum MH; Zain J; Allen SL; Jaffe ES; Ling A; Turner M; Peer CJ; Figg WD; Steinberg SM; Smith S; Joske D; Lewis I; Hutchins L; Craig M; Fojo AT; Wright JJ; Bates SE
Blood; 2011 Jun; 117(22):5827-34. PubMed ID: 21355097
[TBL] [Abstract][Full Text] [Related]
19. Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study.
Maruyama D; Tobinai K; Ogura M; Uchida T; Hatake K; Taniwaki M; Ando K; Tsukasaki K; Ishida T; Kobayashi N; Ishizawa K; Tatsumi Y; Kato K; Kiguchi T; Ikezoe T; Laille E; Ro T; Tamakoshi H; Sakurai S; Ohtsu T
Int J Hematol; 2017 Nov; 106(5):655-665. PubMed ID: 28664499
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors: novel agents in cancer treatment.
Glass E; Viale PH
Clin J Oncol Nurs; 2013 Feb; 17(1):34-40. PubMed ID: 23372094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
